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A B S T R A C T
Purpose: Active convulsive epilepsy (ACE) impacts patients greatly, especially in low-income countries
where patients do not receive appropriate treatment. In the present study, we measured the prevalence
and treatment gap (TG) of ACE in rural West China.
Methods: Six rural areas in West China that have a total population of 3,541,319 were selected to
conduct prevalence and TG estimates of ACE via a clue survey from 2007 to 2009. Clue survey here is a
community-based screening strategy among deﬁned population which requires employed well-trained
local physicians//health workers to collect all clues available to discover/identify/recruit patients within
a study period. Questionnaire-based interviews were used for the identiﬁcation of ACE patients, and
information was obtained during the survey. Prevalence and TG of ACE were calculated.
Results: A total of 6547 patients with ACE were identiﬁed. The estimated prevalence of ACE was 1.8 per
1000 in the general population, with the prevalences in males and females determined to be 2.0 and 1.7,
respectively (p < 0.001). The TG in the general population was 66.3%, and it was 66.6% and 66.0% in males
and females, respectively (p > 0.05). The TG ﬁgures dropped with advancing age and increased above 30
years of age. Patients aged 60 years or older had the largest TG (77.8%); those with disease course less
than 10 years showed a larger TG and those who experienced two to ﬁve seizures annually had a
signiﬁcantly larger TG (70.6%). Additionally, only 63.9% of the ACE patients included in the study were
aware of the disease and had consulted a doctor.
Conclusions: There exists a large TG of ACE in West China rural areas. Majority of those ever consulted a
doctor but failed to receive or adhere to an appropriate treatment program. Management including
public education as well as training of local physicians were necessary to ﬁll that gap.
Crown Copyright  2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Epilepsy is one of the most common chronic neurological
disorders, affecting nearly 50 million people around the world, 80%
of whom live in low-income countries.1 More than 75% of epilepsy
patients in low-income countries do not receive appropriate
treatment. The inability of such patients to receive treatment for
epilepsy is known as treatment gap (TG).2 In China, approximately
9 million people are estimated to have epilepsy, with a lifetime* Corresponding author at: Department of Neurology, West China Hospital,
Sichuan University, Chengdu 610041, Sichuan Province, China.
Tel.: +86 028 85422549; fax: +86 028 85422549.
E-mail address: zjllxx1968@163.com (L. Liu).
1 These authors contributed equally to this study.
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http://dx.doi.org/10.1016/j.seizure.2014.01.007prevalence of 7.0 cases per 1000 people. For active epilepsy, the
lifetime prevalence is 4.6 cases per 1000 people (with a TG of 63%).3
In 1997, as part of the Global Campaign Against Epilepsy
launched by the World Health Organization (WHO) in cooperation
with the International League Against Epilepsy (ILAE) and the
International Bureau for Epilepsy, a project that included an
epidemic survey, an intervention trial, and an educational program
was initiated to study epilepsy in China.4 In 2000, another large-
scale project supported by the government was launched in the
northern and eastern rural areas of China to identify and manage
active convulsive epilepsy (ACE) in these communities. During that
period, two major studies that focused on an efﬁcacy assessment of
phenobarbital and on premature mortality due to epilepsy were
published.5,6 In 2005, a project with the same protocol and design
was extended to the rural areas of West China. Our previous report
on the causes of death from ACE was based on that project.7 As of
this writing, the epidemiologic data on epilepsy have been. Published by Elsevier Ltd. All rights reserved.
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the prevalence and TG of ACE based on the previous extended
project. Although some epidemiological data on this topic has been
reported in northern and eastern areas of China in the past ten
years.3 However in western rural areas of China, no special report
referring to prevalence and TG has been issued. This study provides
a detailed discussion of the epidemiological features of the
prevalence and TG of ACE based on a large rural community-
based survey in West China.
2. Methods
The Institutional Ethics Committee of West China Hospital
provided ethical approval of the project. All participants provided
written consent to participate in the project, and consent was given
by guardians for children (age < 18 years).
Six rural areas in West China with a total population of
3,541,319 were selected to estimate the prevalence and TG of ACE
via a clue survey (Fig. 1). Clue survey here is a community-based
screening strategy among deﬁned population which requires
employed well-trained local physicians//health workers to collect
all clues available to discover/identify/recruit patients within a
study period. A total of 211 local communities (towns/villages) and
541 local primary care physicians were involved in this project.
From 2007 to 2009, all six areas completed the screening process
successively. The screening procedure was limited to one year for
each area, and the study targeted members of the population who
were older than two years of age.
Prior to screening, an operational model of a network for
managing patients with ACE was established to guarantee the
successful completion of the survey.8 Such a network depends on
all existing primary health organizations in which the local, well-
trained primary care physicians were involved. First, free epilepsy
clinics were established in each local community. To ensure that
ACE patients in the overall population were aware of the disease, a
training program for primary care physicians and public
information dissemination, which included distribution ofFig. 1. Administrative map of the Sichuan provincinformational materials, telecasts, and free community medical
consultations, was implemented. By clue survey, possible patients
with ACE were exposed from main four sources: (1) possible ACE
cases visiting the free epilepsy clinics; (2) cases reported by the
visitor with epilepsy or other diseases in clinic, and further
interviewed by the local primary care physicians; (3) suspected
cases provided by local mayor of the village, anti-epidemic
stations, health centers, mental hospital etc., (4) cases collected by
local primary care physicians when they went down to the
villages. After recording the a possible ACE patient based on clinic
visits and witnesses’ clues, a face-to-face interview using a
standard diagnostic panel with proven reliability and validity5
was conducted by local primary care physicians to formulate an
initial diagnosis of ACE. Each local primary health organization
was responsible for screening the hidden patient from the local
community via the clues. An door-to-door survey, although ideal,
was impractical in such vast rural areas. The clue-trace method
was regarded as the optimal manner in which to ﬁnd these
patients because rural patients with similar diseases were likely
to share their treatment experience with each other. Even if
patients did not know each other personally, they were likely to
know about people with similar diseases in the neighboring areas.
The witnesses could tell the local primary care physicians about
the seizures. Additionally, relatives of the patients could visit
clinics for consultation. After the initial diagnosis of ACE made by
the primary care physicians, supervising neurologists were
assigned to each community to identify and screen those
suspected positive cases. Patients with diseases mimicking
epilepsy or patients with partial seizures were excluded from
the study. Finally, information was collected and delivered to the
provincial Centers for Disease Control (CDC), where the data were
checked and stored. In addition, a questionnaire for primary care
physicians was formulated to assess their ability to identify
patients who may potentially suffer from ACE (Additional
Table 1). Five hundred and twelve (94.6% of total) primary care
physicians participated in this investigation, and their average
score was 8.6  2.8, which represents competent diagnoses.e of China highlighting the six survey areas.
Table 1
Demographics of ACE patients (n = 6547).
Mean (SD) or n (%)
Study population
Male 3606 (55.1)
Female 2941 (44.9)
Age (years) 34.8 (16.1)
Age group (years)
2–14 719 (11.0%)
15–44 4176 (63.8%)
45–59 1170 (17.9%)
60 482 (7.3%)
ACE traits
Age of onset (years) 18.3 (14.6)
Disease course (years) 16.5 (12.2)
Seizure frequency (per year) 23.4 (38.6)
Fig. 2. Distribution of ACE in different onset age.
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experienced more than one identiﬁed, unprovoked convulsion
within the 12 months immediately prior to screening. A person
was considered ‘‘untreated’’ if he had not received antiepileptic
drug (AED) treatment or Chinese traditional treatment (such as
acupuncture and herbal medicines) in the month prior to
identiﬁcation of ACE. Appropriate treatment is the regular
treatment of ACE according to national standards, which primarily
involves prescribing AEDs and rarely includes surgery, when
feasible. TG refers to the ratio of the number of patients with ACE
who are not receiving appropriate treatment to the number of all
patients with ACE screened in a given period of time, expressed as a
percentage. The given time was deﬁned as the month prior to the
identiﬁcation of ACE, within which the receipt of appropriate
treatment by a patient is determined.
The data were analyzed using SPSS 17.0 software for Windows.
Chi square tests were used to explore the different frequencies and
rates of gender, age, prevalence and TG in different groups.
Statistical signiﬁcance was set at p < 0.05.
3. Results
Six areas in West China were involved in the survey, and 6547
patients with ACE were identiﬁed (Table 1). Among the ACE
patients, the ratio of males to females was 1.23, compared to a ratio
of 1.08 in the overall population (p < 0.001). The number of ACE
patients was found to decrease as the age of onset increased. At the
age of 20, the number of ACE patients suddenly decreased (Fig. 2).
The majority of ACE patients (4075, 62.6%) had an onset age of less
than 20 years old.
The prevalences and TGs of ACE in the six study areas are
provided in Additional Tables 2 and 3. The prevalence of ACE wasTable 2
Prevalence (%) of ACE in different age brackets.
Age group
(years)
Screening population
Total (Male/Female)
Total 
2–9 512677 (273514/239163) 349 (0.7)
10–19 545753 (287535/258218) 976 (1.8)
20–29 581910 (296086/285824) 1030 (1.8)
30–39 647672 (332382/315290) 1750 (2.7)
40–49 458424 (238852/219572) 1156 (2.5)
50–59 378851 (200609/178242) 805 (2.1)
60–69 243818 (127973/115845) 349 (1.4)
70–79 133685 (6436169324) 118 (0.9)
80 38529 (14356/24173) 14 (0.4)
Total 3541319 (1835668/1705651) 6547 (1.8)1.8 per 1000 in the general population, and the prevalences in
males and females were 2.0 and 1.7, respectively (p < 0.001). The
TG in the general population was 66.3%, and the TG were 66.6 and
66.0 in males and females, respectively (p > 0.05).
Tables 2 and 3 show the prevalence and TG of ACE at different
ages. Prevalence increased as age increased, peaking (2.7 per 1000)
from ages 30 to 39 and declining gradually to 0.4 in the oldest age
group (>80 years old). The prevalence varied between genders
(p < 0.05) in the 10–19 age group and in those older than 59 years
of age. In the population with ACE, TG ﬁgures dropped with
advancing years and increased after 30 years of age. Differences in
TG between genders were found in the following age groups: 10–
29 years old and 70 to 79 years old (p < 0.05).
Table 4 shows the TG information grouped according to age,
disease course, and seizure frequency. The table also provides a
comparison between subgroups within each group. In terms of age
group, patients aged 60 years or older had a larger TG (77.8%) with
a signiﬁcant difference compared with other age groups. Patients
under the age of 15 had the second largest TG (71.2%) with a
statistically signiﬁcant difference. In the disease course group, the
TG in the subgroup of 2–9 years was greater than that in the
subgroup of over 9 years; however, no signiﬁcant difference was
found for the TG between the latter group (1 year) and the others.
In the seizure frequency group, those who experienced two to ﬁve
seizures annually had a signiﬁcantly larger TG (70.6%) than those
who experienced more than ﬁve seizures. Additionally, almost no
difference in TG was observed between genders in each group.
This survey found that 63.9% of the ACE patients included in the
study were aware of the disease to some extent and consulted a
doctor, whereas 36.1% of the ACE patients were not aware of the
disease and did not see a doctor.Male Female p-Value
 197 (0.7) 152 (0.6) 0.246
 576 (2.0) 400 (1.5) <0.001
 502 (1.7) 528 (1.8) 0.168
 931 (2.8) 819 (2.6) 0.115
 625 (2.6) 531 (2.4) 0.181
 454 (2.3) 351 (2.0) 0.050
 234 (1.8) 115 (1.0) <0.001
 78 (1.2) 40 (0.6) <0.001
 9 (0.6) 5 (0.2) 0.036
 3606 (2.0) 2941 (1.7) <0.001
Table 3
TG (%) of ACE in different age brackets.
Age group (years) Total Male Female p-Value
2–9 73.9 76.0 71.1 0.296
10–19 66.9 70.5 61.8 0.004
20–29 61.5 64.5 58.5 0.047
30–39 65.3 63.5 67.3 0.096
40–49 65.4 63.5 67.6 0.145
50–59 65.4 64.5 66.7 0.514
60–69 78.8 77.8 80.9 0.507
70–79 79.0 73.4 90.0 0.036
80 42.9 33.3 60.0 0.334
Total 66.3 66.6 66.0 0.565
Table 5
Treatment of ACE.
Treatment N (%)
Regular AEDs 2204 (33.7)
Old AEDs 2089 (31.9)
Phenytoin 984 (15.0)
Phenobarbital 560 (8.6)
Carbamazepine 677 (10.3)
Valproate 360 (5.5)
New AEDs 175 (2.7)
Inappropriate treatment 2531 (38.7)
Irregular AEDs 1002 (15.3)
Chinese herb 1507 (23.0)
Acupuncture 227 (3.5)
Folk empirical prescription 810 (12.4)
Untreated 1812 (27.7)
New AEDs include Oxcarbazepine, Lamotrigine, Topiramate, etc. Note that one
patient could use more than one therapy, which could include both appropriate and
inappropriate treatments. We categorized those who received regular AEDs and
another inappropriate treatment (irregular AEDs was not included) in the regular
AEDs group.
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treatment, but few used new AEDs. In all of the patients, 27.7% did
not receive any treatment.
4. Discussion
The present study estimates the prevalence of ACE and the TG
using a clue survey method based on large communities because of
the limited manpower and ﬁnancial resources of the study.
However, a door-to-door survey would have been an ideal method
for this study. The prevalence of ACE (rather than partial seizures)
was selected for the study not only because ACE has severe
physical effects that deserve attention but also because establish-
ing a clinical diagnosis for ACE is easier than establishing one for
partial seizures. When diagnosing partial seizures, other disease
entities mimicking epilepsy, such as psychogenic non-epileptic
seizures, would be difﬁcult to exclude.
A slight increase in the prevalence of epilepsy among males is
commonly reported. However, the prevalence of convulsive
epilepsy has rarely been studied. From the few published reports
on the subject, the male-to-female ratio varies from 0.71 to 1.29.6,9
Our ﬁndings conﬁrmed an increased male-to-female ratio among
ACE patients (1.23). Global disparities are present in the prevalence
of epilepsy. At the beginning of this century, one epidemiological
survey on China showed that the lifetime prevalence of epilepsy
was 7 cases per 1000 people.3 Prior to that study, the lifetime
prevalence of epilepsy was found to be between 3 and 5 cases perTable 4
TG (%) comparison in different groups.
Group Total TG Male TG Female TG p-Value
Age group (years)
2–14a 71.2 73.9 67.2 0.051
15–44b 64.1 64.2 64.0 0.887
45–59c 66.5 65.7 67.5 0.515
60d 77.8 75.4 84.5 0.080
Disease course group (years)
1a 69.3 66.8 74.5 0.175
2–4b 72.4 73.9 70.1 0.230
5–9c 68.3 71.7 63.8 0.006
10–19d 64.6 63.5 65.9 0.254
20e 64.4 64.0 64.9 0.627
Seizure frequency group (n/year)
2–5 70.6 70.1 71.4 0.569
6–11 65.7 66.9 64.2 0.324
12–23 65.8 65.6 66.0 0.851
24 63.1 63.7 62.4 0.538
Comparison between subgroups of age: pab< 0.001, pac = 0.033, pad = 0.011,
pbd< 0.001, pcd< 0.001.
Comparison between subgroups of disease course: pbd< 0.001, pbe< 0.001,
pcd = 0.041, pce = 0.029.
Comparison between subgroups of seizure frequency: pab = 0.004, pac = 0.002,
pad< 0.001.
Only those with p < 0.05 were listed.1000, and 4.4 cases per 1000 is often cited.10 Wang’s study on the
prevalence of active epilepsy suggested a prevalence of 4.6 cases
per 1000 people.3 To date, epidemic data on the prevalence of ACE
in China have yet to be reported. Considering that partial epilepsy
contributes to more than half of epilepsy cases in the general
population, the data 1.8 for the prevalence of ACE is to some extent
consistent with Wang’s estimate for active epilepsy, although the
value might be underestimated. Methodological differences could
directly lead to underestimation and it is also possible that patients
with active partial and secondary generalized seizures were
excluded from this estimation. Of course whether the prevalence is
low in the area studied need further investigations. The literature
suggests that the incidence and prevalence of epilepsy is highest in
the elderly.11 Among seizure types, partial epilepsy is known to
occur most frequently in the elderly, and the incidence of general
epilepsy remains low. In the present study, the prevalence of ACE
was found to peak during the ages of 30–39 years and declined
until reaching the lowest value of 0.4 cases per 1000 in the elderly.
Based on those ﬁgures, we can deduce that a number of ACE
patients may experience remission or die before reaching old age,
which can partially explain the low prevalence of ACE in the
elderly. Another important factor that may contribute to the poor
physical status of the elderly is that they may have been unable to
provide accurate information for diagnosis. Additionally, living
alone or in a remote location decreases the likelihood of neighbors
having witnessed an episode and makes it more difﬁcult for
patients to travel to receive treatment. Thus, further studies are
necessary to examine this phenomenon.
According to one systematic review, the worldwide TG for
epilepsy is estimated to be approximately 56%, and more than 90%
of these cases occur in developing countries.12 In China, a door-to-
door epidemic survey found a TG of 63% for active epilepsy.3 Our
survey indicated a TG of 66.3% for ACE, which is consistent with the
previous study conducted in other areas of China. To our
knowledge, there are few detailed studies on the TG for epilepsy.
The present study addresses the research gap and provides an
overview of the subject.
In general, differences in TG between genders were not found.
However, for patients aged 10–19 years, more females received
appropriate treatment, whereas for patients aged 70–79 years,
more males received appropriate treatment. In addition, the lowest
TG was observed in females in the 20–29 age group. This may be
because females of childbearing age receive more medical
attention, but gradually lose this attention as they age. By contrast,
adult males received slightly more appropriate treatment.
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the past, the main labor force in rural China was composed of adult
males who played a central role in the family. Compared with
women, adult males received greater medical attention. However,
the recent situation reﬂected in this study implies that both
genders in the family enjoy almost equal status.
The ILAE concluded that the determinants of TG are diagnostic
and therapeutic deﬁcits, economic conditions, cultural beliefs, and
distance from health facilities.13 These factors were not included in
our research due to the original design of the project. Nevertheless,
the present study describes other factors such as age, disease
course, and seizure frequency. The elderly population with ACE
had the largest TG in the present study, followed by children. This
result suggests that these underserved populations may not be
receiving enough care due to their physical and psychological
vulnerability. We observed that patients who have had epilepsy for
less than one year showed no difference in TG compared to others.
Ten years appeared to be a watershed period that was lower than
the period where TG remained high and vice versa. Inadequate
understanding of the disease and the absence of timely medical
treatment may explain why a substantial number of patients fail to
receive the early treatment that is essential to ensure maximum
remission of seizures. Seizure frequency appeared to inﬂuence the
TG. After experiencing ﬁve seizures per year, patients generally
opted to seek treatment, although appropriate treatment is not
always guaranteed in rural areas. Epilepsy in numerous patients
who experience a lower frequency of seizures may progress into
chronic epilepsy without timely treatment. New AEDs are rarely
used because a majority of patients cannot afford the medication.
In addition, Chinese herbal medicine, which has not proven
effective, comprises the majority of ‘‘inappropriate treatment’’. In
this study, numerous patients who participated in the investiga-
tion did not receive or adhere to an appropriate treatment
program, which reﬂects the need for public education as well as the
training of local physicians.
Limitations
Reporting on the prevalence using a subset of patients from a
much wider pool of people with all forms of epilepsy without a
meticulous etiological diagnostic work up affected the scientiﬁc
cache.14 The clue survey used for the estimation of prevalence had
its weakness and limitations. On one hand, it might fail to screen
out all patients with ACE and underestimate the prevalence in
those areas. On the other hand, such method was focused on the
ACE and unable to detect all forms of epilepsy. According to the
rules of epilepsy project, our cohort lose the information of those
with age less than two years. Also in the present study, diagnosis
was mainly based on the clinical situation. Laboratory tests,
electroencephalogram, and imaging examinations were rarelyapplied which might affect a deﬁnite diagnosis. As regard to TG,
considering the purpose of the project is to identify and manage
those patients with ACE, complete information were not required
to obtain, thus factors associated with TG were unable to
recognize. In the future, a door-to-door survey is needed for the
accurate estimation of the prevalence. Also exploring potential
factors related to TG are beneﬁt for the better management of
epilepsy.
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